Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 1 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.533 | 0.4775 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.3135 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1062 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1062 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.1062 | 0.1062 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1062 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.3135 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1062 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1062 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1062 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.3135 | 0.2319 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1062 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.3135 | 0.2319 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.533 | 1 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.3135 | 0.2319 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.3135 | 0.2319 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.3135 | 0.2319 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.3135 | 0.5 |
Brugia malayi | hypothetical protein | 0.003 | 0.3135 | 0.3135 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1062 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.533 | 0.4775 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.3233 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.